Phase I trial of interleukin 2 in combination with the soluble tumor necrosis factor receptor p75 IgG chimera

Clinical Cancer Research

Volumn 2, Issue 8, 1996, Pages 1341-1351

  Trehu, Elizabeth G ^a   Mier, James W ^a   Dubois, Jon S ^a   Sorce, Damian ^a   Klempner, Mark S ^a   Epstein, Mark ^a   Dinarello, Charles A ^a   Shapiro, Leland ^a   Kappler, Kerry ^a   Ronayne, Lucie ^a   Atkins, Michael B ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ANTIBODY RESPONSE; ARTICLE; CANCER CHEMOTHERAPY; CAPILLARY PERMEABILITY; CELL INFILTRATION; CHEMOTAXIS; CHIMERA; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE CALCULATION; DOSE RESPONSE; FEMALE; HUMAN; IMMUNOMODULATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; AGED; FEMALE; HLA-DR ANTIGENS; HUMANS; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-2; MALE; MIDDLE AGED; NEOPLASMS; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT PROTEINS;

EID: 9544240332     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Parkinson, D. R., Fisher, R. I., Rayner, A. A., Paietta, E., Margolin, K. A., Weiss, G. R., Mier, J. W., Sznol, M., Gaynor, E. R., and Bar, M. H. Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen. J. Clin. Oncol., 8: 1630-1636, 1990.
2. Parkinson, D. R., Abrams, J. S., Wiernik, P. H., Rayner, A. A., Margolin, K. A., Van Echo, D. A., Sznol, M., Dutcher, J. P., Aronson, F. R., Doroshow, J. H., Atkins, M. B., and Hawkins, M. J. Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study. J. Clin. Oncol., 8: 1650-1656, 1990.
3. Fisher, R. I., Coltman, C. A., Jr., Doroshow, J. H., Raynor, A. A., Hawkins, M. J., Mier, J. W., Wiernik, P., McMannis, J. D., Weiss, G. R., Margolin, K. A., Gemlo, B. T., Hoth, D. F., Parkinson, D. R., and Paietta, E. Metastatic renal cell cancer treated with interleukin-2 and lymphokine-activated killer cells: a phase II clinical trial. Ann. Intern. Med., 108: 518-523, 1988.
4. Bar, M. H., Sznol, M., Atkins, M. B., Ciobanu, N., Micetich, K. C., Boldt, D. H , Margolin, K. A., Aronson, F. R., Rayner, A. A., Hawkins, M. J., Mier, J. W , Paietta, E., Fisher, R. I., Weiss, G. R., and Doroshow, J. H. Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells. J. Clin. Oncol , 8. 1138-1147, 1990.
5. Atkins, M. B , Mier, J. W., Parkinson, D. R., Gould, J. A., Berkman, E. M., and Kaplan, M. M. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N. Engl. J Med., 318: 1557-1563, 1988.
6. Dutcher, J. P., Creekmore, S., Weiss, G. R., Margolin, K., Markowitz, A B., Roper, M , Parkinson, D., Ciobanu, N., Fisher, R. I., Boldt, D. H., Doroshow, J. H., Rayner, A. A., Hawkins, M., and Atkins, M. A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. J. Clin. Oncol., 7: 477-485, 1989.
7. Rosenberg, S. A., Mule, J. J , Spiess, P. J., Reichert, C. M., and Schwarz, S. L. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemid administration of high-dose recombinant interleukin-2. J. Exp. Med., 161: 1169-1188, 1985.
8. Bradley, E. C., Louie, A. C., Paradise, C. M., Carlin, D. A., Bleyl, K. L., Groves, E. S., and Rudolph, A. R. Antitumor response in patients with metastatic renal cell carcinoma is dependent upon regimen intensity. Proc. Am. Soc. Clin. Oncol. 8: 133, 1989.
9. Parkinson, D. R. Interleukin-2 in cancer therapy. Semin. Oncol., 15 (Suppl. 6): 10-26, 1988.
10. Margolin, K. A., Rayner, A. A., Hawkins, M J., Atkins, M. B., Dutcher, J. P., Fisher, R. I., Weiss, G. R., Doroshow, J. H., Jaffe, H. S., Roper, M., Parkinson, D. R., Wiernik, P. H., Creekmore, S. P., and Boldt, D. H. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J. Clin. Oncol., 7: 486-498, 1989.
11. Fyfe, G., Fisher, R I., Rosenberg, S. A., Sznol, M., Parkinson, D. R., and Louie, A. C. Results of treatment of 255 patients with metastatic renal cell cardinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol., 13: 688-696, 1995.
12. Atkins, M. B., Gould, J. A., Allegretta, M., Li, J. J., Dempsey, R. A., Rudders, R. A., Parkinsons, D. R., Reichlin, S., and Mier, J. W., Phase I evaluation of recombinant interleukin-2 in patients with advanced malignant disease. J. Clin. Oncol , 4: 1380-1391, 1986.
13. Mier, J. W., Dinarello, C. A., Atkins, M. B., Punsal, P. I., and Perlmutter, D. H. Regulation of hepatic acute phase protein synthesis by products of interleukin-2 (IL-2) stimulated human peripheral blood mononuclear cells. J. Immunol., 139: 1268-1272, 1987.
14. Cotran, R. S., Pober, J. S., Gimbrone, M. A., Springer, T. A., Wiebke, E. A., Gaspari, A. A., Rosenberg, S. A., and Lotze, M. T. Endothelial activation during interleukin-2 immunotherapy: a possible mechanism for the vascular leak syndrome. J. Immunol., 140: 1883-1888, 1988.
15. Numerof, R. P., Aronson, F. R., and Mier, J. W. IL-2 stimulates the production of IL-1 α and IL-1 β by human peripheral blood mononuclear cells. J. Immunol., 141: 4250-4257, 1988.
16. Numerof, R. P., Kotik, A. N., Dinarello, C. A., and Mier, J. W. Pro-interleukin-1 β production by a subpopulation of human T cells, but not NK cells, in response to interleukin-2. Cell. Immunol., 130: 118-128, 1990.
17. Mier, J. W., Vachino, G., van der Meer, J. W., Numerof, R. P., Adams, S., Cannon, J. G., Bernheim, H. A., Atkins, M. B., Parkinsons, D. R., and Dinarello, C. A. Induction of circulating tumor necrosis factor (TNF α) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients. J. Clin. Immunol., 8: 426-436, 1988.
18. Nedwin, G. E., Svedersky, L. P., Bringman, T. S., Paladino, M. A., Jr., and Goeddel, D. V Effect of interleukin-2, interferon-γ, and mitogens on the production of tumor necrosis factors α and β. J. Immunol., 135: 2492-2497, 1985.
19. Hibbs, J. B., Westenfelder, C., Taintor, R., Vavrin, Z., Kablitz, C., Baranowski, R. L., Ward, J. H., Menlove, R. L., McMurry, M. P., Kushner, J. P., and Samlowski, W. E. Evidence for cytokine-inducible nitric oxide synthesis from L-arginine in patients receiving interleukin-2 therapy. J. Clin. Invest., 89: 867-877, 1992.
20. Cox, G. W., Melillo, G., Chattopadhyay, U., Mullet, D., Fertel, R. H., and Varesio, L. Tumor necrosis factor-α-dependent production of reactive nitrogen intermediates mediates IFN-gamma plus IL-2-induced murine macrophage tumoricidal activity. J. Immunol., 149: 3290-3296, 1992.
21. Mier, J., Vachino, G., Numerof, R , and Atkins, M. Mechanisms of action and therapeutic applications of biologicals in cancer and immune deficiency, UCLA. In: J. Groopman, C. Evans, and D. Golde (eds.), Symposia on Molecular and Cellular Biology, Vol. 100, pp. 153-162, New York: Alan R. Liss, Inc., 1989.
22. Mier, J. W., Vachino, G., Klempner, M. S., Aronsons, F. R , Noring, R., Smith, S., Brandon, E. P., Laird, W, and Atkins, M. B. Inhibition of interleukin-2 induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotactic defect and differential suppression of interleukin-2 associated side effects. Blood, 76: 1933-1940, 1990.
23. Fraker, D. L., Langstein, H. N., and Norton, J. A. Passive immunization against tumor necrosis factor partially abbrogates interleukin 2 toxicity. J. Exp. Med., 170: 1015-1020, 1989.
24. Fraker, D. L., Thom, A. K., Doherty, G. M., Langstein, H. N., Buresh, C. M., and Norton, J. A. Tumor necrosis factor mediates the survival benefit of interleukin-2 in a murine pulmonary metastates model. Surg. Oncol., 1: 1-9, 1992.
25. Dower, S. K., Smith, C. A , and Park, L. S. Human cytokine receptors. J. Clin. Immunol., 10. 289-299, 1990.
26. Smith, C. A., Davis, T., Anderson, D., Solam, L., Beckmann, M. P., Jerzy, R., Dower, S. K., Cosman, D., and Goodwin, R. G. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science (Washington DC), 248: 1019-1023, 1990.
27. Mohler, K. M., Torrance, D. S., Smith, C. A., Goodwin, R. G., Stremler, K. E., Fung, V. P., Madani, H., and Widmer, M. B. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J. Immunol., 151: 1548-1561, 1993.
28. Tilg, H., Shapiro, L., Vannier, E., Poutsiaka, D. D., Trehu, E., Atkins., M. B., Dinarello, C. A., and Mier, J. W.. Induction of circulating antagonists to IL-1 and TNF by IL-2 administration and their effects on IL-2-induced cytokine production in vitro. J. Immunol., 152: 3189-3198, 1994.
29. van der Meer, J. W., Endres, S., Lonneman, G., Cannon, J. G., Ikejima, T., Okusawa, S., Gelfand, J. A., and Dinarello, C. A Concentrations of immunoreactive tumor necrosis factor-α produced by human monunuclear cells in vitro J. Leukocyte Biol., 43: 216-223, 1988.
30. Poutsiaka, D. D., Clark, B. D., Vanmer, E., and Dinarello, C. A. Production of interleukin-1 receptor antagonist and interleukin-1β by peripheral blood mononuclear cells is differentially regulated. Blood, 78: 1275-1281, 1991.
31. Schindler, R., Mancilla, J., Endres, S., Ghorbani, R., Clark, S. C., and Dinarello, C. A. Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood, 75: 40-47, 1990.
32. Porat, R., Poutsiaka, D. D., Miller, L. C., Granowitz, E V , and Dinarello, C. A. Interleukin-1 (IL-1) receptor blockade reduces endotoxin and Borrelia tergutorferi-stimulated IL-8 synthesis in human mononuclear cells. FASEB J., 6: 2482-2486, 1992.
33. Hogan, M. M , and Vogel, S. N. Measurement of tumor necrosis factor α and β. In: J. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, and W. Strober (eds.), Current Protocols in Immunology, pp. 6.10.1-6.10.5. New York: John Wiley & Sons, 1994.
34. Bartholomew, B. A rapid method for the assay of nitrate in urine using the nitrate reductase enzyme of Escherichia coli. Food Chem. Toxicol., 22: 541-543, 1984.
35. Granger, D. L., Hibbs, J. B., Perfect, J. R., and Durack, D T. Metabolic fate of L-arginine in relation to microbiostatic capability of murine macrophages. J. Clin. Invest., 85: 264-273, 1990.
36. Klempner, M. S., Noring, R., Mier, J. W., and Atkins, M. B. An acquired chemotactic defect in neutrophils. from patients receiving interleukin-2 immunotherapy. N. Engl. J. Med., 322: 959-965, 1990.
37. DeLellis, R. A., Sternberger, L. A., Mann, R. B., Banks, P. M , and Nakane, P. K. Immunoperoxidase technics in diagnostic pathology. Report of a workshop sponsored by the National Cancer Institute. Am. J Clin. Pathol., 71: 483-488, 1979.
38. Hsu, S. M., Raine, L., and Fanger, H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J. Histochem. Cytochem., 29: 577-580, 1981.
39. Jablons, D. M., Mule, J. J., McIntosh, J. K., Sehgal, P. B., May, L. T., Huang, C. M., Rosenberg, S. A., and Lotze, M. T. IL-6/IFN-β-2 as a circulating hormone: induction by cytokine administration in humans. J. Immunol., 142: 1542-1547, 1989.
40. Tilg, H., Shapiro, L., Atkins, M. B., Dinarello, C. A., and Mier, J. W. Induction of circulating and erythrocyte-bound IL-8 by IL-2 immunotherapy and suppression of its in vitro production by IL-1 receptor antagonist and soluble TNF receptor (p75)-chimera. J. Immunol., 151: 3299-3307, 1993.
41. Atkins, M. B., Sparano, J., Fisher, R. I., Weiss, G. R., Margolin, K. A., Fink, K. I., Rubinstein, L., Louie, A., Mier, J. W., Gucalp, R., Sosman, J. A., Boldt, D. H., Doroshow, J. H., Aronson, F. R., and Sznol, M. Randomized phase II trial of high-dose Interleukin-2 either alone or in combination with interferon α-2b in advanced renal cell carcinoma. J. Clin. Oncol., 11: 661-670, 1993.
42. Sparano, J. A., Fisher, R. I., Sunderland, M., Margolin, K., Ernest, M. L., Sznol, M., Atkins, M. B., Dutcher, J P., Micetich, K. C., Weiss, G. R., Doroshow, J H., Aronson, F. R., Rubinstein, L. V., and Mier, J. W. Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon α-2a in patients with advanced melanoma. J. Clin. Oncol., 11: 1969-1977, 1993.
43. Numerof, R. P., Sipe, J. D., Trehu, E. G., Dinarello, C. A., and Mier, I. W. Suppression of IL-2-induced SAA gene expression in mice by the administration of an IL-1 receptor antagonist. Cytokine, 4: 555-560, 1992.
44. Hechtman, D. H., Cybulsky, M. I., Fuchs, H. J , Baker, J. B., and Gimbrone, M. A., Jr. Intravascular IL-8: inhibitor of polymorphonuclear leukocyte accumulation at sites of acute inflammation. J. Immunol., 147: 883-892, 1991.
45. G-methyl-L-argimne inhibits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxide. Proc. Natl. Acad. Sci. USA, 87: 3629-3632, 1990.
46. G-methyl-L-arginine causes endothelium-dependent contraction and inhibition of cyclic GMP formation in artery and vein. Proc. Natl. Acad. Sci. USA, 87. 4430-4434, 1990.
47. G-Methylarginine, an inhibitor of endothelium-derived nitric oxide synthesis, is a potent pressor agent in the guinea pig: does nitric oxide regulate blood pressure in vivo? Biochem. Biophys. Res. Commun., 160: 881-886, 1989.
48. Ignarro, L. J. Endothelium-derived nitric oxide: actions and properties. FASEB J., 3: 31-36, 1989.
49. Vallance, P., Collier, J., Moncada, S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet, 2: 997-1000, 1989.
50. G-Methyl-L-arginine, an inhibitor of nitnc oxide synthase, reverses interleukin-2 induced hypotension. Crit. Care Med., 23: 1018-1024, 1995.
51. Rubin, J. T., Elwood, L. J., Rosenberg, S. A., and Lotze, M. T. Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans. Cancer Res., 49: 7086-7092, 1989.
52. Pfizenmaier, K., Scheurich, P., Schluter, C., and Kronke, M. Tumor necrosis factor enhances HLA-A, B, C, and HLA-DR expression in human tumor cells. J. Immunol., 138: 975-980, 1987.
53. Boccoli, G., Masciulli, R., Ruggeri, E. M., Carlini, P., Giannella G., Montesoro, E , Mastroberardino, G., Isacchi, G., Testa, U., Calabresi, F., and Peschle, C. Adoptive immunotherapy of human cancer: the cytokine cascade and monocyte activation following high-dose Interleukin 2 bolus treatment. Cancer Res., 50: 5795-5800, 1990.